Investment
Features
FeesSafety
Academy
More
Pluang+

ADMA Biologics sees 24% ASCENIV revenue growth in Q2 despite lowered long-term targets

Company Fundamentals
12 Aug 2026
Seeking Alpha
View Source
Bullish
pluang ai news

ADMA Biologics experienced challenges earlier this year but showed recovery in Q2 with ASCENIV revenue up 24% and a strong 69% gross margin. The company lowered its long-term targets but improved receivable collections have boosted investor confidence. The stock is valued with a conservative target price of $12.70–$13, suggesting about 30% upside based on continued ASCENIV growth rather than a return to previous guidance. This outlook supports a cautious buy stance amid ongoing growth potential from ASCENIV.

More News (ADMA)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App